Clinical Trial Update: Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating mesenchymal stem cells as the first-line therapy for resistant acute graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Graft vs Host Disease | Phase 2 | Status: UNKNOWN